Anidulafungin
- TRADE NAMES: Ecalta (Pfizer); Eraxis (Pfizer)
- INDICATIONS: Candidemia, candidal esophagitis
- CLASS: Antimycobacterial; echinocandin
- HALF-LIFE: 40–50 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric